Serodus Is A Private Scandinavian Drug Development Company With A Pipeline Focusing On Novelimmuno Modulators Stopping Progression Of Diabetic Kidney Desease Lead Candidate Ser150 Targets Diabetic Kidney Diseaserepresenting An Attractive Market And Significant Recognized Unmet Medical Needser150 Showed Positive Phase 2A Development Resultsa Confirmatory Clinical Study Is Expected To Start During 2021 H1All Currently Available Treatments For T2D Are Initially Effective In Reducing Blood Glucose And Reduce Complication Ratesbut They Lack The Ability To Stop The Systemic Inflammation Driving The Pathophysiological Processes Of Diabetes And Its Complicationsour Candidates Target The Fundamental Underlying Systemic Inflammation Causing Diabetes And Its Comorbidities
